However, even the novel vitamin D analogs are not neutral with regards to the risk of hypercalcemia development.[47] Cinacalcet, a variant G protein-coupled receptor modulator that activates CaSR, efficiently decreases serum calcium and PTH in CKD-associated SHPT. This evidence concerns the gene CASR and hypercalcemia disease.